Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
Alger Health Sciences Fund
AHSCX (Mutual Fund)
Alger Health Sciences Fund
Name
As of 12/24/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
1.7%
1 yr return
2.9%
3 Yr Avg Return
-7.7%
5 Yr Avg Return
0.8%
Net Assets
$116 M
Holdings in Top 10
49.2%
52 WEEK LOW AND HIGH
$12.8
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 2.15%
SALES FEES
Front Load N/A
Deferred Load 1.00%
TRADING FEES
Turnover 152.78%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000
IRA
$500
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 12/24/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
AHSCX - Profile
Distributions
- YTD Total Return 1.7%
- 3 Yr Annualized Total Return -7.7%
- 5 Yr Annualized Total Return 0.8%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -1.39%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameAlger Health Sciences Fund
-
Fund Family NameAlger Family of Funds
-
Inception DateMay 01, 2002
-
Shares OutstandingN/A
-
Share ClassC
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerDaniel Chung
Fund Description
The Manager believes companies undergoing Positive Dynamic Change offer the best opportunities. Positive Dynamic Change refers to companies realizing High Unit Volume Growth or companies undergoing Positive Lifecycle Change. High Unit Volume Growth companies are traditional growth companies experiencing, for example, rapidly growing demand or market dominance. Positive Lifecycle Change companies are, for example, companies benefitting from new regulations, a new product innovation or new management.Under normal circumstances, the Fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. Equity securities include common or preferred stocks that are listed on U.S. or foreign exchanges. A company will be considered to be engaged in the health sciences sector if it derives at least 50% of its earnings or revenues from, or devotes at least 50% of its assets to, activities in any area of the health sciences sector, including health care services, pharmaceuticals, medical equipment and supplies and applied research and development. Such companies include, but are not limited to:•hospitals, clinical test laboratories, convalescent and mental health care facilities, home care providers, and companies that supply services to any of the foregoing;•companies involved in pharmaceuticals, biotechnology, biochemistry and diagnostics; and•producers and manufacturers of medical, dental and optical supplies and equipment.The Fund may invest a substantial portion of its assets in a smaller number of issuers. Fund holdings may occasionally increase or decrease for a variety of reasons, including, among others, because of extreme market volatility, such as when the Fund has entered a temporary defensive position. Additionally, the Fund may exceed its current number of holdings when it acquires a new holding and determines that it is in the best interests of shareholders to sell an existing holding over a period of time, instead of immediately selling the entire holding.The Fund may sell a stock when it reaches a target price, it fails to perform as expected, or other opportunities appear more attractive. As a result, the Fund may engage in active trading of portfolio securities.The Fund can also invest in privately placed securities, which are securities acquired in non-public offerings for which there is no readily available market.The Fund can invest in foreign securities.The Fund invests in cash (and cash equivalents) when the Fund is unable to find enough attractive long-term investments to meet its investment objective, to meet redemptions and/or when the Manager believes it is advisable to do so during times of short-term market volatility. During these times, cash (and cash equivalents) will not exceed 15% of the Fund’s net assets.
Read More
AHSCX - Performance
Return Ranking - Trailing
| Period | AHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 1.7% | -26.3% | 19.5% | 60.38% |
| 1 Yr | 2.9% | -26.3% | 19.1% | 56.60% |
| 3 Yr | -7.7%* | -27.7% | 7.4% | 88.82% |
| 5 Yr | 0.8%* | -11.1% | 10.9% | 85.91% |
| 10 Yr | 3.3%* | -0.8% | 12.6% | 88.60% |
* Annualized
Return Ranking - Calendar
| Period | AHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -5.1% | -12.6% | 19.0% | 94.34% |
| 2022 | -17.7% | -53.9% | 3.2% | 81.58% |
| 2021 | -29.4% | -39.6% | 24.2% | 98.68% |
| 2020 | 11.5% | -13.6% | 178.2% | 59.06% |
| 2019 | 10.7% | 3.8% | 63.8% | 95.49% |
Total Return Ranking - Trailing
| Period | AHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 1.7% | -26.3% | 19.5% | 60.38% |
| 1 Yr | 2.9% | -26.3% | 19.1% | 56.60% |
| 3 Yr | -7.7%* | -27.7% | 7.4% | 88.82% |
| 5 Yr | 0.8%* | -11.1% | 10.9% | 85.91% |
| 10 Yr | 3.3%* | -0.8% | 12.6% | 88.60% |
* Annualized
Total Return Ranking - Calendar
| Period | AHSCX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -5.1% | -12.6% | 19.0% | 95.60% |
| 2022 | -17.7% | -53.9% | 3.7% | 85.53% |
| 2021 | 1.7% | -33.9% | 26.0% | 75.66% |
| 2020 | 30.0% | -0.7% | 180.6% | 33.56% |
| 2019 | 21.1% | 4.6% | 63.8% | 82.71% |
NAV & Total Return History
AHSCX - Holdings
Concentration Analysis
| AHSCX | Category Low | Category High | AHSCX % Rank | |
|---|---|---|---|---|
| Net Assets | 116 M | 6.43 M | 45.7 B | 73.58% |
| Number of Holdings | 43 | 25 | 430 | 85.53% |
| Net Assets in Top 10 | 52.1 M | 2.55 M | 23.9 B | 72.33% |
| Weighting of Top 10 | 49.24% | 18.9% | 78.1% | 37.74% |
Top 10 Holdings
- UnitedHealth Group Inc 6.55%
- Amgen Inc 6.34%
- AstraZeneca PLC 5.10%
- AbbVie Inc 4.84%
- McKesson Corp 4.76%
- Regeneron Pharmaceuticals Inc 4.67%
- Eli Lilly Co 4.63%
- Merck Co Inc 4.33%
- Vertex Pharmaceuticals Inc 4.30%
- ICON PLC 3.71%
Asset Allocation
| Weighting | Return Low | Return High | AHSCX % Rank | |
|---|---|---|---|---|
| Stocks | 96.84% | 89.92% | 106.13% | 74.21% |
| Cash | 3.16% | 0.00% | 33.01% | 38.99% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 62.89% |
| Other | 0.00% | -22.99% | 23.24% | 63.52% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 47.40% |
| Bonds | 0.00% | 0.00% | 12.39% | 60.38% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | AHSCX % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 24.68% |
| Utilities | 0.00% | 0.00% | 0.00% | 43.51% |
| Technology | 0.00% | 0.00% | 22.69% | 46.10% |
| Real Estate | 0.00% | 0.00% | 5.89% | 47.40% |
| Industrials | 0.00% | 0.00% | 7.02% | 47.40% |
| Financial Services | 0.00% | 0.00% | 1.60% | 60.39% |
| Energy | 0.00% | 0.00% | 0.00% | 43.51% |
| Communication Services | 0.00% | 0.00% | 9.11% | 46.75% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 50.65% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 47.40% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 62.34% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | AHSCX % Rank | |
|---|---|---|---|---|
| US | 94.45% | 61.27% | 104.41% | 47.80% |
| Non US | 2.39% | 0.00% | 34.10% | 51.57% |
AHSCX - Expenses
Operational Fees
| AHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 2.15% | 0.08% | 4.48% | 15.09% |
| Management Fee | 0.55% | 0.03% | 1.25% | 20.75% |
| 12b-1 Fee | 1.00% | 0.00% | 1.00% | 85.71% |
| Administrative Fee | 0.03% | 0.03% | 0.25% | 5.41% |
Sales Fees
| AHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | 1.00% | 1.00% | 1.00% | 45.00% |
Trading Fees
| AHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | 21.95% |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| AHSCX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 152.78% | 0.00% | 238.00% | 96.30% |
AHSCX - Distributions
Dividend Yield Analysis
| AHSCX | Category Low | Category High | AHSCX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.24% | 62.26% |
Dividend Distribution Analysis
| AHSCX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | SemiAnnual | Annual |
Net Income Ratio Analysis
| AHSCX | Category Low | Category High | AHSCX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -1.39% | -2.54% | 1.85% | 94.08% |
Capital Gain Distribution Analysis
| AHSCX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 15, 2021 | $7.001 | OrdinaryDividend |
| Dec 16, 2020 | $3.753 | OrdinaryDividend |
| Dec 18, 2019 | $1.914 | CapitalGainLongTerm |
| Dec 18, 2018 | $0.242 | CapitalGainShortTerm |
| Dec 18, 2018 | $1.640 | CapitalGainLongTerm |
| Dec 19, 2006 | $0.720 | CapitalGainLongTerm |
| Dec 20, 2005 | $0.234 | CapitalGainShortTerm |
| Dec 20, 2005 | $0.115 | CapitalGainLongTerm |
| Dec 17, 2004 | $0.533 | CapitalGainShortTerm |
| Dec 17, 2004 | $0.165 | CapitalGainLongTerm |
| Dec 19, 2003 | $0.200 | CapitalGainShortTerm |
| Dec 19, 2003 | $0.034 | CapitalGainLongTerm |
AHSCX - Fund Manager Analysis
Managers
Daniel Chung
Start Date
Tenure
Tenure Rank
Oct 01, 2005
16.67
16.7%
Dan Chung, CFA is Chief Executive Officer, Chief Investment Officer and Portfolio Manager of several Alger strategies. Dan joined Alger in 1994 and has 27 years of investment experience. He was named Chief Investment Officer in September 2001, President in 2003, and CEO in 2006. Dan is also a member of The Alger Partners Plan. Throughout his tenure at Alger, he has made numerous TV appearances on Bloomberg, CNBC, and Fox Business. Dan has also been featured and quoted frequently in Barron’s, Citywire, Forbes, Investment News, Pensions & Investments, and USA Today. Prior to joining Alger, Dan was an associate at Simpson Thacher & Bartlett LLP in New York City in 1989 while he earned an LL.M. from New York University. He earned his J.D. magna cum laude from Harvard Law School in 1987, where he was an editor of the Harvard Law Review. After graduating, he served as law clerk for the Honorable Justice Anthony M. Kennedy, United States Supreme Court. Dan graduated from Stanford University with B.A. and B.S. degrees, with Distinction and Phi Beta Kappa, in 1984. Dan is also a CFA charterholder and a member of the CFA Institute. Dan currently serves as a board trustee and former chairman of The Nature Conservancy in the State of New York and is a Global Campaign Committee Member of The Nature Conservancy. He is also actively involved with the Stanford in New York Internship Program, and frequently contributes to and supports various charitable organizations including the Harlem Education Activities Fund (HEAF) and Target Margin Theater.
Sanjiv Talwar
Start Date
Tenure
Tenure Rank
Jul 01, 2021
0.92
0.9%
Dr. Sanjiv Talwar is Senior Vice President, Senior Analyst, Portfolio Manager of the Alger Health Sciences and Large Cap Growth strategies and the Head of Healthcare. He joined Alger in 2021 with 15 years of investment experience and more than 12 years of experience in scientific and medical research. Before joining Alger, Sanjiv was a Portfolio Manager, Senior Analyst and Director of Equity Research for Oppenheimer Funds, a life sciences fund from 2012 to 2021 at Invesco, where he also served as a Senior Healthcare Analyst on a global fund. Prior to that, Sanjiv was an Associate Principal at McKinsey & Company from 2006 to 2012, where he led consulting teams focused on healthcare, serving industry and private equity globally.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |
